Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Assessing the Safety, Tolerability and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease Subjects Not Receiving Memantine Treatment
NCT03560245 is registered in ClinicalTrials.gov with Neurotrope Bioscience, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Assessing the Safety, Tolerability and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease Subjects Not Receiving Memantine Treatment
- Lead sponsor
- Neurotrope Bioscience, Inc.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- June 20, 2018
- Completion date
- July 25, 2019
- Enrollment
- 108 (actual)
- Sites
- 28
Conditions
As the registry lists them; a condition with its own page is linked.